Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
Vaxart (NASDAQ: VXRT) has scheduled its full year 2024 business update and financial results conference call for March 20, 2025, after market close. The conference call will begin at 4:30 p.m. ET, featuring the senior management team.
Investors can participate through domestic line (877) 407-0832 or international line (201) 689-8433 using Conference ID 13751819. Questions can be submitted in advance to ir@vaxart.com. A webcast replay will be available on the company's website after the event.
Vaxart (NASDAQ: VXRT) ha programmato l'aggiornamento aziendale e la conferenza sui risultati finanziari per l'intero anno 2024 per il 20 marzo 2025, dopo la chiusura del mercato. La conferenza inizierà alle 16:30 ET, con la partecipazione del team di gestione senior.
Gli investitori possono partecipare tramite la linea nazionale (877) 407-0832 o la linea internazionale (201) 689-8433 utilizzando l'ID Conferenza 13751819. Le domande possono essere inviate in anticipo a ir@vaxart.com. Una registrazione della webcast sarà disponibile sul sito web dell'azienda dopo l'evento.
Vaxart (NASDAQ: VXRT) ha programado su actualización empresarial y la conferencia de resultados financieros para todo el año 2024 para el 20 de marzo de 2025, después del cierre del mercado. La conferencia comenzará a las 4:30 p.m. ET, con la participación del equipo de alta dirección.
Los inversores pueden participar a través de la línea nacional (877) 407-0832 o la línea internacional (201) 689-8433 utilizando el ID de Conferencia 13751819. Las preguntas se pueden enviar por adelantado a ir@vaxart.com. Una repetición de la transmisión web estará disponible en el sitio web de la empresa después del evento.
Vaxart (NASDAQ: VXRT)는 2024년 전체 사업 업데이트 및 재무 결과 컨퍼런스 콜을 2025년 3월 20일 시장 종료 후로 예정했습니다. 컨퍼런스 콜은 오후 4:30 ET에 시작되며, 고위 경영진 팀이 참여합니다.
투자자들은 국내 전화 (877) 407-0832 또는 국제 전화 (201) 689-8433을 통해 컨퍼런스 ID 13751819를 사용하여 참여할 수 있습니다. 질문은 ir@vaxart.com으로 미리 제출할 수 있습니다. 이벤트 후 회사 웹사이트에서 웹캐스트 재방송이 제공될 예정입니다.
Vaxart (NASDAQ: VXRT) a programmé sa mise à jour commerciale et sa conférence sur les résultats financiers pour l'année complète 2024 pour le 20 mars 2025, après la clôture du marché. La conférence débutera à 16h30 ET, avec la participation de l'équipe de direction senior.
Les investisseurs peuvent participer par la ligne nationale (877) 407-0832 ou la ligne internationale (201) 689-8433 en utilisant l'ID de conférence 13751819. Les questions peuvent être soumises à l'avance à ir@vaxart.com. Un enregistrement de la diffusion en direct sera disponible sur le site Web de l'entreprise après l'événement.
Vaxart (NASDAQ: VXRT) hat sein Geschäftsupdate und die Telefonkonferenz zu den finanziellen Ergebnissen für das Gesamtjahr 2024 für den 20. März 2025 nach Börsenschluss angesetzt. Die Telefonkonferenz beginnt um 16:30 Uhr ET und wird vom Führungsteam geleitet.
Investoren können über die nationale Leitung (877) 407-0832 oder die internationale Leitung (201) 689-8433 mit der Konferenz-ID 13751819 teilnehmen. Fragen können im Voraus an ir@vaxart.com gesendet werden. Eine Aufzeichnung des Webcasts wird nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
Conference call to begin at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2024 after the market close on Thursday, March 20, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.
The conference call can be accessed using the following information:
Webcast: Click here
Date: Thursday, March 20, 2025 – 4:30 p.m. ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13751819
Investors may submit written questions in advance of the conference call to ir@vaxart.com.
A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
FAQ
When will Vaxart (VXRT) release its full year 2024 financial results?
What time is Vaxart's (VXRT) earnings conference call scheduled for March 20, 2025?
How can investors participate in Vaxart's (VXRT) 2024 earnings call?
Can investors submit questions for Vaxart's (VXRT) 2024 earnings call?
